17th International Workshop on Pediatrics & HIV 2025

• Co-submission of abstracts with IAS 2025 is allowed. You can submit your abstract(s) to both Pediatrics & HIV 2025 and IAS 2025 as long as you comply with the IAS 2025 embargo policy. The co-submission agreement does not apply to IAS 2025 late-breaker abstracts.

• The 17th International Workshop on Pediatrics & HIV 2025 will be hosted at Park Inn by Radisson Kigali.
  
  Full Address: Avenue de Kiyovu & Res des Parcs Plot 5457, Kigali, Rwanda

• Registration and Abstract Submission are now open!

• To stay updated on the relevant developments, make sure you are signed up for our newsletter. 

The 17th International Workshop on Pediatrics & HIV will take place in a hybrid format from 11-12 July 2025 in Kigali, Rwanda.

Although we have witnessed a dramatic global scale-up of antiretroviral treatment (ART) as well as efforts to prevent vertical HIV transmission in the last decade, there were 150,000 new pediatric infections in 2021 and an estimated 1.68 million children <15 years of age living with HIV. Children are substantially less likely than adults to be diagnosed, initiate treatment, and achieve durable viral suppression. Currently, only 54% are receiving ART, and treatment of pediatric HIV, particularly in infants and young children, remains complex and problematic, with continued use of suboptimal ART formulations and regimens.

Furthermore, adolescents are one of the most rapidly growing populations with HIV; in 2021, there were an estimated 410,000 new HIV infections among young people aged 15- 24 years, accounting for 27% of all new HIV infections globally. HIV infections among adolescent girls and young women are 65% higher than among adolescent boys and young men of the same age, with 4,900 new infections occurring in young women weekly. HIV remains one of the leading causes of death among adolescents living in Africa and among the top 10 causes of death in adolescents globally. The uptake of HIV testing among adolescents has remained low. Programs continue to struggle to reach and retain adolescents in care, and adherence to treatment has special challenges, particularly among those with perinatal infection aging up into adolescence and young adulthood.

As research to improve pediatric HIV diagnosis and care is ongoing, new scientific questions of critical importance have also emerged. In settings with mature ART programs, an increasing proportion of new pediatric infections is attributed to women acquiring HIV infection during pregnancy and breastfeeding, periods of markedly increased risk of HIV acquisition for the mother.  However, the use of newer, highly effective long-acting pre-exposure prophylaxis (PrEP) drugs to prevent HIV acquisition has been limited in pregnant and breastfeeding women due to the limited available data on the pharmacokinetics and safety of these drug during these periods and limited availability in low resource settings where most women with HIV reside.   The introduction of the new long-acting agents for treatment and prevention provides important opportunities to identify innovative new approaches and address the next generation of questions around implementation, uptake, and persistence in adolescents and pregnant and breastfeeding people.  The use of newer potent ART regimens, such as dolutegravir, by women living with HIV may affect the sensitivity of rapid nucleic acid diagnostic tests, complicating infant diagnosis.

Additionally, with more than 1.3 million pregnant women globally receiving ART, a new set of questions about the long-term impact of in utero and postnatal exposures to medications for those children HIV-exposed but uninfected (CHEU) are emerging.  Currently, the global population of HIV-exposed uninfected children and adolescents is estimated at 14.8 million, including over 8 million with in-utero ARV exposure. The importance of surveillance of the safety of new ARVs in pregnancy is underscored by the initial signal of an association of neural tube defects with periconception dolutegravir exposure which was shown to be erroneous after sufficient numbers of exposures had been documented.

Innovation in early infant diagnosis such as point-of-care tests has facilitated earlier identification of HIV infection during infancy, providing exciting new opportunities to study acute infection and very early treatment in neonates and promising remission strategies.

However, despite the critical importance of these topics, research in pediatric, adolescent, and maternal HIV infection is often neglected at major scientific HIV conferences. Therefore, in collaboration with leading experts in the field, we continue our highly focused international workshop on the prevention and treatment of pediatric HIV.

The overall objective of the International Workshop on Pediatrics & HIV is to stimulate research that will advance prevention and treatment strategies for infants, children, and adolescents.  The workshop aims to provide a platform for presentation and discussion of the latest developments in the field, to gather experts involved in pediatric and perinatal HIV, and to promote both diversity and the next generation of research in the field  The workshop has been highly effective in attracting presentation of top-level research in pediatric and maternal HIV; of 248 oral abstracts presented at the past workshops in 2013-2023, 148 (60%) have resulted in scientific publications. 

General Information 

Practical Information 

*Countries included in the low-income and middle-income economies list of the World Bank Classification

Important

• We strongly advise that you register early to ensure your registration. Registration will close when the capacity of the venue is reached.

• Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

• Co-submission of abstracts with IAS 2025 is allowed. You can submit your abstract(s) to both Pediatrics & HIV 2025 and IAS 2025 as long as you comply with the IAS 2025 embargo policy. The co-submission agreement does not apply to IAS 2025 late-breaker abstracts.

• Pediatrics & HIV 2025 accepts new original data as well as encored abstracts. All abstracts must focus on Pediatrics & HIV and contain up-to-date information at the time of the workshop. 

• We are pleased to offer 50% discount on the Early Fee for early-career investigators and academia from low-income and lower-middle-income countries with an accepted abstract. The requirements for the application are specified here.

• Abstract submitters are strongly encouraged to use person-first language in their abstracts. View the video tutorial and guidelines here

• Abstract presenters are expected to attend the workshop in-person to present their abstract. Please contact the workshop secretariat if this is not possible.

We are proud to present the members of the committee:

• Adam Bartlett, BSc, MBBS, MPHTM, PhD, FRACP - Sydney Children's Hospital / Kirby Institute, Australia

• Ulrich von Both, MD, FRCPCH - Dr. von Hauner Children's Hospital, Germany

• Jason Brophy, MD, MSc, DTM, FRCPC - Children's Hospital of Eastern Ontario, Canada

• Ellen Chadwick, MD - Ann & Robert H. Lurie Children’s Hospital of Chicago / Northwestern University Feinberg School of Medicine, United States

• Anita De Rossi, PhD - University of Padova / Istituto Oncologico Veneto (IOV)-IRCCS, Italy

• Marinella Della Negra, MD, PhD - Hospital Emilio Ribas, Brazil

• Brian Eley, MD - University of Cape Town, South Africa

• Albert Faye, PhD - Denis Diderot University, Paris, France

• Rashida Ferrand, MBBS, FRCP, PhD - London School of Hygiene and Tropical Medicine / Biomedical Research and Training Institute, Zimbabwe

• Patricia Flynn, MD - St. Jude Children's Research Hospital, United States

• Tessa Goetghebuer, MD - Office de la Naissance et de l'Enfance / CHU Saint-Pierree, Belgium

• Ali Judd, PhD, University College London, United Kingdom

• Valériane Leroy, MD - Inserm, Paris, France

• Chewe Luo, MD, PhD - UNICEF, United States

• Dorothy Mbori-Ngacha, MBChB, MMed, MPH - Independent Consultant, Kenya

• Immaculate Mutisya, MMed - Centres for Disease Control and Prevention, Kenya

• Sharon Nachman, MD - SUNY Stony Brook / IMPAACT, United States

• Tim Niehues, MD, Helios Centre for Child and Adolescent Health, Krefeld, Germany

• Clare Nourse, AM, BA, MB, BCH, BAO DCH, MRCPI, FRACP, MD - Children's Health Queensland / University of Queensland, Australia

• Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, United States

• Martina Penazzato, MD, MSc, PhD - World Health Organization, Switzerland

• Kathleen Powis, MD, Massachusetts General Hospital, United States

• Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Elizabeth Glaser Pediatrics AIDS Foundation / Children’s National Hospital, United States

• Theodore Ruel, MD - UCSF Benioff Children's Hospital San Francisco, United States

• George Siberry, MD, MPH, FAAP, FPIDS - United States Agency for International Development (USAID), United States

• Lynda Stranix-Chibanda, MBChB, MMed - University of Zimbabwe, Zimbabwe

• Tavitiya Sudjaritruk, MD, ScM, PhD - Chiang Mai University, Thailand

• Graham Taylor, MD - Imperial College, United Kingdom

• Claire Thorne, BA, MSc, PhD - University College London, United Kingdom

• Priscilla Tsondai, MBChB and MPH, International AIDS Society, South Africa

• Rachel Vreeman, MD, MS - Icahn School of Medicine at Mount Sinai, United States

Virology Education (VE), with support from the industry, is offering scholarships  to attend Pediatrics & HIV 2025 from 11-12 July 2025 in Kigali, Rwanda.

The scholarships are supported by industry. These companies will have no control, influence, or involvement in selection of any attendees.

Virology Education is proud to support participation from professionals from underrepresented communities. We strongly recognize the value of conducting our programs with a diverse and inclusive representation of the scientific and medical global community, welcoming a range of backgrounds, experiences, and opinions and embracing the benefits that these differences bring. This diversity and equity are essential to our mission of advancing clinical care and scientific research worldwide.

Read our Code of Conduct

• Registration Scholarship: 

• Registration only

• Partial Scholarship:

• Registration
• Accommodation

• Full Scholarship:

• Registration
• Accommodation
• Travel

All scholarship awardees are required to attend the full meetings. Awardees must sign in at the beginning of each meeting day and sign off at the end of each day as requested by the Workshop Organizer. At the close of the Conference, awardees must have completed the daily and overall conference evaluations.

Recipient will provide post-meeting feedback and a summary about his/her conference experience within one month after the end of the workshop. The feedback questionnaire will be an online survey with the recipient providing feedback on their experience at the workshop, scholarship procedure, and how they will implement the knowledge acquired at the meeting in their daily practice. The questionnaire will be sent to each recipient by email within one week after the conclusion of the workshop.

Applicants must:

• Be proficient in English to interact with faculty and fellow attendees
• Be actively involved in the field of Pediatrics & HIV
• Be able to show benefits to their patients / research / community from attending the meeting
• Be willing and able to share information learned at the meetings with a larger community
• Be eligible to obtain a visa for travel. Declare that she/he is able and willing to fund all other costs beyond the scholarship that are involved in attending the workshop, e.g. all other hotel, travel and subsistence expenses NOT covered by the scholarship.
• Declare to take out her/his own insurance policies (for travel, liability, illness and/or other necessary insurances in relation to her/his participation to the conference).
• Workshop organizer will automatically decline all scholarship applications that do not conform to the eligibility terms

The scholarship applications must be submitted online through our Scholarship Application Portal by 25 April 2025. The applicant will be asked to submit a motivational letter (max. 200 words) describing how their patients/research/community will benefit from the knowledge gained at these meetings, and their knowledge dissemination strategy, a CV, and a letter of recommendation (optional).

• All applications will be acknowledged upon receipt.
• All applications will be reviewed by an independent Scholarship Review Committee
• Successful applicants will be sent a scholarship agreement.
• After receipt of the signed scholarship agreement, successful applicants will receive instructions for travel arrangements.
• All applicants will receive notification of the application status no later than 1 month prior to the meeting they are planning to attend.

• Professional background
• Quality of the abstract (if accepted)
• Country of residence
• Recommendation by your supervisor
• Demonstrable benefits to patients / research / community by the knowledge to be gained at this meeting
• Strategy of knowledge dissemination
• Early-Career Investigator

• Incomplete applications will not be considered. Workshop Organizer cannot be held responsible for any incorrect information that is submitted through the scholarship application portal.
• All travel arrangements will be made by Workshop Organizer in collaboration with their preferred business travel partner. Workshop Organizer cannot reimburse any travel costs made by participants themselves.
• Retrospective applications will not be considered.
• Scholarship recipients must attend the entire conferences.
• Scholarship recipients are committed to attend the meetings in person. If they fail to do so, they will be charged the full amount of the travel and accommodation costs incurred and will be excluded from applications for future scholarships of Workshop Organizer.
• Scholarships are non-transferrable.
• Workshop Organizer cannot guarantee awarding the scholarship to prospective scholarship recipients until the confirmation of available funds. In the event that sufficient funding for the scholarship is not available, Workshop Organizer will not be liable for any expenses or damages incurred by the prospective scholarship recipient with regards to the scholarship application and/or preparation for the meeting.
• Applications will be considered until the exhaustion of funds.
• Scholarship recipients will be responsible for all other costs associated with conference attendance.
• Workshop Organizer will not be liable for any injury, death, damage, loss, delay, cost, expense, or inconvenience, causes of action claims and suits for property damage, theft of property or personal injury (including death) arising in connection with the scholarship and participation in the workshop.
• Workshop Organizer reserves the right to make the final decision regarding all applications, which cannot be disputed.

Pediatrics & HIV 2025 is endorsed by societies and organizations. Their support and collaboration are key to the success of this workshop!

If you would like your organization to endorse the International Workshop on Pediatrics & HIV 2025, please contact Magda Sevlidou at magda.sevlidou@amededu.com 

Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in Pediatrics & HIV.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Ms. Karin Siebelt at Karin.Siebelt@amededu.com. 
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

• Symposium opportunities
• Non-commercial interviews with company representatives
• Verbal acknowledgement during the program 
• Discounted and complimentary registrations for your representatives
• Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
• Company acknowledgement on printed meeting materials including but not limited to banners and the program book
• Digital and printed advertising opportunities 
• Social media shout-outs
• Logo on the conference bag 

 
*Subject to the support level.

• 16th Edition - International Workshop on Pediatrics & HIV 2024, Germany
• 15th Edition - International Workshop on HIV & Pediatrics 2023, Australia
• 14th Edition - International Workshop on HIV Pediatrics, 2022, Canada
• 13th Edition - International Workshop on HIV Pediatrics, 2021, Virtual
• 12th Edition - International Workshop on HIV Pediatrics, 2020, Virtual
• 11th Edition - International Workshop on HIV Pediatrics, 2019, United States
• 10th Edition - International Workshop on HIV Pediatrics, 2018, The Netherlands
• 9th Edition - International Workshop on HIV Pediatrics, 2017, France
• 8th Edition - International Workshop on HIV Pediatrics, 2016, South Africa
• 7th Edition - International Workshop on HIV Pediatrics, 2015, Canada